Skip to main content
Clinical Trials/NCT06976788
NCT06976788
Recruiting
Not Applicable

Creation of a Database of Healthy Subjects With 18FDG PET Brain Imaging as Part of the MOBILE Project (Multimodal Whole-Brain Imaging in Epilepsy)

Assistance Publique Hopitaux De Marseille1 site in 1 country30 target enrollmentStarted: September 26, 2024Last updated:

Overview

Phase
Not Applicable
Status
Recruiting
Enrollment
30
Locations
1
Primary Endpoint
cerebral glucose consumption

Overview

Brief Summary

The MOBILE project is part of the dynamic European collaboration of the Human Brain Project (HBP). The overall aim of the project is to characterize brain structure and function in healthy subjects and patients with epilepsy, using a quantitative multimodal approach involving both neuroimaging (MRI, PET) and electrophysiology (EEG/MEG). The project is funded by the European HBP consortium, and the data acquired will ultimately be made available to the scientific community formed by this international collaboration. Several aspects of the project have already been initiated on the basis of extensions to previous authorizations, or as part of care activities. As part of this overall project, the present MOBILE-PET application concerns exclusively the performance of 18F-FDG PET (Positron Emission Tomography) imaging in the 30 healthy adult subjects in the protocol (aged 18 to 65, with inclusion parity for gender). This cerebral examination, performed at rest on a 45-minute 3D volume acquisition, enables quantitative measurement of the metabolic consumption of glucose underlying global synaptic activity, and to determine the associated connectivity. Around 1,500 examinations of this type are carried out each year in our department as part of care for patients with brain pathology, and over 10,000 for patients with cancer. This examination requires intravenous injection of a weakly radioactive tracer corresponding to a radiopharmaceutical which has been approved for marketing for over 20 years. We also carried out and finalized a similar project in 2007 on 60 healthy subjects, using a previous-generation PET camera (NCT00484523). The Nuclear Medicine Department holds clinical research authorizations for imaging in patients and healthy subjects (including early phase and first-in-man, although the present project does not fall into this research categarogy).

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Basic Science
Masking
None

Eligibility Criteria

Ages
18 Years to 65 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • - Female or male, over 18 and under 65 years of age.
  • Subject free of any general illness, psychiatric disorders or infectious, inflammatory, tumoral, vascular, degenerative or traumatic pathology of the central nervous system, as determined on examination,
  • Subject not receiving chronic treatment, particularly psychotropic,
  • Subject with no history of alcoholism or drug addiction,
  • Subject with no contraindications to PET scintigraphic exploration (pregnancy and breast-feeding),
  • Subject with social security coverage,
  • Subject having read, understood and signed an informed consent form.

Exclusion Criteria

  • - Minors,
  • Pregnant or breast-feeding women,
  • Women of childbearing age without contraception,
  • Subjects presenting a contraindication to PET scintigraphic exploration,
  • adult subject to a legal protection measure, as provided for in L.1121-6 to L.1121-8 of the French Public Health Code.

Outcomes

Primary Outcomes

cerebral glucose consumption

Time Frame: Baseline and 24 months (longitudinal follow-up)

Secondary Outcomes

  • Metabolic connectivity(Baseline and 24 months (longitudinal follow-up))

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials